Atea Pharmaceuticals, Inc.
AVIR
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleosiā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.70
Price-0.84%
-$0.04
1Y
Price
Market Cap
$376.127m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-25.0%
5y CAGREarnings
-$169.517m
+12.7%
1y CAGR-9.5%
3y CAGR-56.0%
5y CAGREPS
-$2.11
+11.5%
1y CAGR-9.5%
3y CAGR-57.5%
5y CAGRBook Value
$233.709m
$267.076m
Assets$33.367m
Liabilities$634k
DebtDebt to Assets
0.2%
-
Debt to EBITDAFree Cash Flow
-$147.859m
+1.0%
1y CAGR-9.1%
3y CAGR-17.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company